155 related articles for article (PubMed ID: 34324022)
1. Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in β-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotype.
Shokrgozar N; Karimi M; Golmoghaddam H; Rezaei N; Moayed V; Sharifzadeh S; Arandi N
Ann Hematol; 2021 Oct; 100(10):2463-2469. PubMed ID: 34324022
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of regulatory T cells frequency and FoxP3/GDF-15 gene expression in β-thalassemia major patients with and without alloantibody; correlation with serum ferritin and folate levels.
Shokrgozar N; Amirian N; Ranjbaran R; Bazrafshan A; Sharifzadeh S
Ann Hematol; 2020 Mar; 99(3):421-429. PubMed ID: 31984437
[TBL] [Abstract][Full Text] [Related]
3. Novel Effector Phenotype of Tim-3
Liu Z; McMichael EL; Shayan G; Li J; Chen K; Srivastava R; Kane LP; Lu B; Ferris RL
Clin Cancer Res; 2018 Sep; 24(18):4529-4538. PubMed ID: 29712685
[No Abstract] [Full Text] [Related]
4. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.
Asano T; Meguri Y; Yoshioka T; Kishi Y; Iwamoto M; Nakamura M; Sando Y; Yagita H; Koreth J; Kim HT; Alyea EP; Armand P; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Maeda Y; Tanimoto M; Ritz J; Matsuoka KI
Blood; 2017 Apr; 129(15):2186-2197. PubMed ID: 28151427
[TBL] [Abstract][Full Text] [Related]
5. Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes.
Kamal AM; Wasfey EF; Elghamry WR; Sabry OM; Elghobary HA; Radwan SM
Clin Biochem; 2021 Oct; 96():13-18. PubMed ID: 34217699
[TBL] [Abstract][Full Text] [Related]
6. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
7. Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis.
Yu Y; Chen Z; Wang Y; Li Y; Lu J; Cui L; Yu Z; Ding Y; Guo C; Zhang X; Shi Y
Int Immunopharmacol; 2021 Jul; 96():107722. PubMed ID: 33965878
[TBL] [Abstract][Full Text] [Related]
8. Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis.
Lavon I; Heli C; Brill L; Charbit H; Vaknin-Dembinsky A
Front Immunol; 2019; 10():835. PubMed ID: 31134049
[No Abstract] [Full Text] [Related]
9. Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
Wang H; Mao L; Zhang T; Zhang L; Wu Y; Guo W; Hu J; Ju H; Ren G
J Oral Pathol Med; 2019 Sep; 48(8):669-676. PubMed ID: 31132187
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
[TBL] [Abstract][Full Text] [Related]
11. Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells.
Gautron AS; Dominguez-Villar M; de Marcken M; Hafler DA
Eur J Immunol; 2014 Sep; 44(9):2703-2711. PubMed ID: 24838857
[TBL] [Abstract][Full Text] [Related]
12. Regulatory T cells demonstrate significantly increased functions following stimulation with IL-2 in a Tim-3-dependent manner in intracranial aneurysms.
Zhang HF; Liang GB; Zhao MG; Zhao GF; Luo YH
Int Immunopharmacol; 2018 Dec; 65():342-347. PubMed ID: 30366277
[TBL] [Abstract][Full Text] [Related]
13. Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.
Linedale R; Schmidt C; King BT; Ganko AG; Simpson F; Panizza BJ; Leggatt GR
PLoS One; 2017; 12(4):e0175755. PubMed ID: 28423034
[TBL] [Abstract][Full Text] [Related]
14. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival.
Tu L; Guan R; Yang H; Zhou Y; Hong W; Ma L; Zhao G; Yu M
Int J Cancer; 2020 Jul; 147(2):423-439. PubMed ID: 31721169
[TBL] [Abstract][Full Text] [Related]
16. Exposure to Plasmodium vivax is associated with the increased expression of exhaustion markers on γδ T lymphocytes.
Gogoi D; Biswas D; Borkakoty B; Mahanta J
Parasite Immunol; 2018 Dec; 40(12):e12594. PubMed ID: 30276843
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Expression of Immune Checkpoints; CTLA-4, LAG3, and TIM-3 in Cancer Cells and Tumor-infiltrating Lymphocytes (TILs) in Colorectal Carcinoma.
Abdelrahman DI; Elhasadi I; Anbaig A; Bakry A; Mandour D; Wasefy T; Yehia AM; Alorini M; Shalaby AM; Yahia AIO; Alabiad MA
Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):71-83. PubMed ID: 38108390
[TBL] [Abstract][Full Text] [Related]
18. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia.
Irani YD; Kok CH; Clarson J; Shanmuganathan N; Branford S; Yeung DT; Ross DM; Hughes TP; Yong ASM
Blood Adv; 2023 Jun; 7(11):2364-2374. PubMed ID: 36622326
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors.
Park HJ; Kusnadi A; Lee EJ; Kim WW; Cho BC; Lee IJ; Seong J; Ha SJ
Cell Immunol; 2012; 278(1-2):76-83. PubMed ID: 23121978
[TBL] [Abstract][Full Text] [Related]
20. Expression level of immune checkpoint inhibitory factors in preeclampsia.
Madadi S; Mohammadinejad S; Alizadegan A; Hojjat-Farsangi M; Dolati S; Samadi Kafil H; Jadidi-Niaragh F; Soltani-Zangbar MS; Motavalli R; Etemadi J; Eghbal-Fard S; Aghebati-Maleki L; Danaii S; Taghavi S; Yousefi M
Hum Immunol; 2022; 83(8-9):628-636. PubMed ID: 35906120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]